Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments.

Saturday, May 31, 2025 7:55 am ET1min read
CHRS--
MRK--
TOI--

Coherus BioSciences has rebranded as Coherus Oncology, focusing exclusively on innovative cancer treatments. The company's pipeline includes FDA-approved LOQTORZI and other promising candidates targeting various cancers. Coherus Oncology is backed by a prestigious team from leading institutions and companies like Merck and the Cancer Research Institute. The rebranding aligns with its strategic focus on developing proprietary cancer therapeutics with higher potential margins and market opportunities.

Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet